REVB — Revelation Biosciences Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Revelation Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12 | 10.9 | 8.66 | 7.98 | 9.07 |
| Operating Profit | -12 | -10.9 | -8.66 | -7.98 | -9.07 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12 | -10.8 | -0.12 | -15 | -8.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12 | -10.8 | -0.12 | -15 | -8.91 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12 | -10.8 | -0.12 | -15 | -8.91 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -12 | -10.8 | -0.12 | -15 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -102,691 | -115,734 | -101 | -1,052 | -21.2 |
| Dividends per Share |